Welcome to Optimum TV!
Bringing you bitesize content from life science leaders hosted by Optimum’s very own Stephen Adams. Talking trends, innovation, capital markets and more…
Tune in, subscribe and share.
Episode 17
Targeting brain cancer using a high-precision radiopharmaceutical
With Greg Mullen, COO of Ariceum Therapeutics
Episode 16
A novel way to tackle Huntington’s disease
With David Reynolds, CEO of LoQus23 Therapeutics
Episode 15
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 5
With Allan Marchington, MD and Head of Life Sciences at ICG
Episode 14
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 4
With Francesco De Rubertis, co-founder and Partner at Medicxi
Episode 13
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 3
With Dr Daniel Mahony, Partner at Novo Holdings
Episode 12
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 2
With Geraldine O’Keeffe, Partner at EQT
Episode 11
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 1
With Kieran Murphy, Chair of Gamma Biosciences, SPT Labtech and Centiva
Episode 10
How a pill can boost the chance of having a baby following IVF / ICSI fertility treatment
With Dr Agnès Arbat, Co-founder and CEO of Oxolife
Episode 9
How does a British biotech raise £90m in a Series A? It’s as easy as ADC.
With Michael Bauer, Partner at Novo Holdings Venture Investments
Episode 8
New treatment beckons for cutaneous T-cell lymphoma (CTCL)
With Jason Loveridge, CEO of 4SC
Episode 7
Creating exceptional antibody-based drugs by interrogating the immune responses of ‘elite responders’ to disease
Joined by Stefano Gullà, CSO of Kling Biotherapeutics
Episode 6
Harnessing the body’s complement system to tackle cancer and autoimmune disease
Joined by Krishna Polu, CEO of Commit Bio
Episode 5
Modifying RNA with small molecule drugs: a new approach to immunotherapy
Joined by Jerry McMahon, CEO of STORM Therapeutics
Episode 4
How to “build” a new blood vessel- the natural way
Joined by Eliane Shutte, CEO of Xeltis
Episode 3
Using cell therapy to revolutionise treatment of end-stage liver disease
Joined by Amir Hefni, CEO of Resolution Therapeutics
Episode 2
How to get the most out of the 2024 spring conference season
Joined by Nick Bastin, Optimum Strategic Communications
Episode 1
Has spring finally sprung for biotech markets?
Joined by Eva Haas, Optimum Strategic Communications
